Pembrolizumab improves outcomes in high-risk bladder cancer
Pembrolizumab nearly doubles cancer-free duration post-invasive bladder surgery, offering a crucial treatment option for high-risk patients.
Combination Therapy May Improve Outcomes for Advanced Bladder Cancer - News Center
Combination therapy of pembrolizumab chemotherapy and oncolytic adenovirus shows promise for immunotherapy-resistant non-muscle-invasive bladder cancer.
Combination Treatment Extends Survival in Advanced Bladder Cancer - News Center
Immunotherapy combined with chemotherapy and surgery significantly improves survival in muscle-invasive bladder cancer patients compared to chemotherapy alone.
FDA approves bladder cancer treatment by Culver City company
FDA approved new bladder cancer treatment Anktiva by ImmunityBio, activating immune response in patients who didn't respond to prior therapies.
Pembrolizumab improves outcomes in high-risk bladder cancer
Pembrolizumab nearly doubles cancer-free duration post-invasive bladder surgery, offering a crucial treatment option for high-risk patients.
Combination Therapy May Improve Outcomes for Advanced Bladder Cancer - News Center
Combination therapy of pembrolizumab chemotherapy and oncolytic adenovirus shows promise for immunotherapy-resistant non-muscle-invasive bladder cancer.
Combination Treatment Extends Survival in Advanced Bladder Cancer - News Center
Immunotherapy combined with chemotherapy and surgery significantly improves survival in muscle-invasive bladder cancer patients compared to chemotherapy alone.
FDA approves bladder cancer treatment by Culver City company
FDA approved new bladder cancer treatment Anktiva by ImmunityBio, activating immune response in patients who didn't respond to prior therapies.